摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Carbonic acid, pentyl 2,2,2-trichloroethyl ester

中文名称
——
中文别名
——
英文名称
Carbonic acid, pentyl 2,2,2-trichloroethyl ester
英文别名
pentyl 2,2,2-trichloroethyl carbonate
Carbonic acid, pentyl 2,2,2-trichloroethyl ester化学式
CAS
——
化学式
C8H13Cl3O3
mdl
——
分子量
263.5
InChiKey
DFFYJVUSHVRNPF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    14
  • 可旋转键数:
    7
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • TRI-FUNCTIONAL UV-ABSORBING COMPOUNDS AND USE THEREOF
    申请人:Domschke Angelika Maria
    公开号:US20100168359A1
    公开(公告)日:2010-07-01
    Described herein are tri-functional compounds useful in the production of ophthalmic lenses. The compounds are composed of UV absorber having a polymerization initiator directly or indirectly bonded to the ultraviolet absorber, and an olefinic group directly or indirectly bonded to the ultraviolet absorber. Also described herein are polymers and ophthalmic lenses produced from the tri-functional compounds described herein.
    本文描述了一种在生产眼镜镜片中有用的三功能化合物。这些化合物由具有聚合引发剂直接或间接连接到紫外线吸收剂的UV吸收剂以及直接或间接连接到紫外线吸收剂的烯烃基组成。本文还描述了从所述三功能化合物制备的聚合物和眼镜镜片。
  • [EN] METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES<br/>[FR] PROCÉDÉS DE SYNTHÈSE DE DÉRIVÉS Z DE PRÉCURSEUR DE MOLYBDOPTÉRINE
    申请人:ALEXION PHARMA INC
    公开号:WO2012112922A1
    公开(公告)日:2012-08-23
    Provided herein are synthetic methods for preparing a compound of formula (I): Also provided herein are synthetic methods for preparing a compound of formula (XIII): The disclosure also provides useful intermediates, derivatives, prodrugs, and pharmaceutically acceptable salts, solvates and hydrates of the formula (I) and formula (XIII) compounds. These compounds are useful for treating diseases associated with molybdenum cofactor deficiency.
    本文提供了制备式(I)化合物的合成方法。本文还提供了制备式(XIII)化合物的合成方法。本公开还提供了式(I)和式(XIII)化合物的有用中间体、衍生物、前药和药用可接受的盐、溶剂合物和合物。这些化合物可用于治疗与辅因子缺乏相关的疾病。
  • ORGANIC SOLAR CELL AND METHOD FOR MANUFACTURING SAME
    申请人:LG CHEM, LTD.
    公开号:US20160343956A1
    公开(公告)日:2016-11-24
    The present specification relates to an organic solar cell and a method for preparing the same. Specifically, an organic solar cell according to the present specification may be prepared by a solution process, and may include a photoactive layer which has a strong binding force due to a hydrogen bond and is excellent in crystallinity. Accordingly, the organic solar cell according to the present specification may exhibit characteristics which are excellent in driving voltage, current, service life, and the like.
    本说明书涉及一种有机太阳能电池及其制备方法。具体而言,本说明书中的有机太阳能电池可以通过溶液法制备,并且可以包括由于氢键具有强大结合力且具有优异晶体性的光活性层。因此,根据本说明书,该有机太阳能电池可以表现出优异的驱动电压、电流、使用寿命等特性。
  • Synthetic process for the manufacture of an ecteinaschidin compound
    申请人:Francesch Andres
    公开号:US20060111570A1
    公开(公告)日:2006-05-25
    Processes are provided for preparing compounds with a fused ring structure of formula (XIV). Such products include ecteinascidins and have a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction.
    提供了制备式(XIV)融合环结构化合物的过程。这些产品包括ecteinascidins,并具有螺环胺-1,4-桥。该过程涉及使用一种1-不稳定、10-羟基、18-保护羟基、双-6,8-烯-5-酮融合环化合物形成1,4桥。在形成1,4桥后,移除C-18保护,然后引入螺环胺。
  • Nuclear receptor binding agents
    申请人:Dalton James T.
    公开号:US20090030036A1
    公开(公告)日:2009-01-29
    The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBAs are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, oxidative stress related disorders such as Parkinson's and stroke, neurological disorders, ophthalamic disorders, cardiovascular disease, and obesity.
    本发明涉及一种新型的核受体结合剂(NRBAs)。这些NRBAs适用于预防和/或治疗各种疾病和病症,包括预防和治疗癌症(如前列腺癌和乳腺癌)、骨质疏松症、激素相关疾病、炎症性疾病、氧化应激相关疾病(如帕森病和中风)、神经系统疾病、眼科疾病、心血管疾病和肥胖症。
查看更多